BioSpace News Archive

Business

Bill Gates Makes Plea to Healthcare Capitalists, Biotechs to Help Change the World

Bill Gates addressed thousands of top executives, bankers and investors at JPM this week.

January 11, 2018
·
1 min read
Drug Development

Sage Therapeutics Looks to File NDA for Postpartum Depression Treatment Later This Year

During the J.P. Morgan Healthcare Conference, Sage provided an update on its long-term strategy to drive growth at the company.

January 11, 2018
·
3 min read
·
Alex Keown
Business

Mind-Controlled Industrial Robo: BrainCo Debuts Cutting-Edge BMI Technologies at CES 2018

BrainCo revealed a BMI integrated robotic arm at CES 2018, gaining attention from a variety of news sources.

January 11, 2018
·
3 min read
Drug Development

Helsinn Group and MEI Pharma Announce That Pracinostat Has Received Orphan Drug Designation From the EMA for the Treatment of AML

The orphan drug designation is based on the scarcity of treatments for patients suffering from AMLand on positive Phase 2 study results.

January 11, 2018
·
8 min read
PharmaFluidics Scores 7.3M Euro to Expand Commercialization of Novel Micro-Chip Device for Biomarker, Diagnostics and Drug Development Applications

The company will focus on intensifying international growth, supported by initial, promising sales.

January 11, 2018
·
3 min read
Pharm Country

MYOS RENS Technology CEO Issues Shareholder Letter

The CEO of MYOS RENS Technology Joseph Mannello, issued the following letter to shareholders.

January 11, 2018
·
7 min read
Business

BioLegend and New York Genome Center Enter into Exclusive Global License and Research Agreement for CITE-seq, a Novel Technique for Multidimensional Single Cell Analysis

BioLegend (“BioLegend”) and the New York Genome Center (“NYGC”) announced today that they have entered into an exclusive worldwide license and collaborative research agreement for CITE-seq technology for use in the research field.

January 11, 2018
·
4 min read
Business

Forty Seven to Collaborate with Merck KGaA, Darmstadt, Germany, on a Novel Immuno-Oncology Combination for Ovarian Cancer

Forty Seven today announced an agreement with Merck KGaA, Darmstadt, Germany to conduct a Phase 1b clinical trial combining Hu5F9-G4 with avelumab* in patients with ovarian cancer.

January 11, 2018
·
5 min read
Policy

Elanco, Aratana Announce Marketing Authorization of GALLIPRANT (grapiprant tablets) in Europe

Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States.

January 11, 2018
·
3 min read
Bio NC

DILIsym Services Inc., a Simulations Plus Company, Releases DILIsym Version 7A

DILIsym Services Inc. announced that it has released Version 7A of its flagship QSP (quantitative systems pharmacology) modeling program, DILIsym.

January 11, 2018
·
5 min read